Efficacy and safety of aspacytarabine (BST-236) as a single-agent, first-line therapy for patients with acute myeloid leukemia unfit for standard chemotherapy.

Jessica K. Altman,Jamie Koprivnikar,James K. McCloskey,Vamsi Kota,Olga Frankfurt,Ashkan Emadi,Dale L. Bixby,Micah M. Burch,Moshe Y. Levy,Selina M. Luger,Tsila Zuckerman,Bhavana Bhatnagar,Ofir Wolach,Chezi Ganzel,Itai Levi,Anna Gourevitch,Ruth Ben Yakar,Shoshi Tessler,Liat Flaishon,Jacob M. Rowe

Efficacy and safety of aspacytarabine (BST-236) as a single-agent, first-line therapy for patients with acute myeloid leukemia unfit for standard chemotherapy.

2021

7007Background: Aspacytarabine (BST-236) is a prodrug of cytarabine, the backbone of acute myeloid leukemia (AML) standard of care chemotherapy, associated with toxicity which precludes its adminis...

Keywords:

Medicine
Internal medicine
Toxicity
single agent
Chemotherapy
Oncology
Myeloid leukemia
standard of care
Cytarabine
Prodrug
first line therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations